Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $8.92, for a total transaction of $17,840.00. Following the transaction, the chief executive officer now owns 14,625,350 shares in the company, valued at approximately $130,458,122. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Thomas Sandgaard also recently made the following trade(s):

• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00.

Zynex Trading Up 1.5 %

Zynex stock opened at $8.76 on Friday. The company’s fifty day simple moving average is $8.11 and its 200-day simple moving average is $9.09. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a 12 month low of $7.15 and a 12 month high of $13.77. The stock has a market cap of $279.01 million, a P/E ratio of 58.40 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The business had revenue of $49.97 million for the quarter, compared to analysts’ expectations of $50.83 million. During the same period in the previous year, the company posted $0.10 EPS. Zynex’s revenue was up .1% on a year-over-year basis. As a group, sell-side analysts forecast that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HC Wainwright lifted their price objective on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada lowered their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Institutional Investors Weigh In On Zynex

Several institutional investors and hedge funds have recently modified their holdings of ZYXI. Millennium Management LLC lifted its stake in shares of Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after purchasing an additional 118,615 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Zynex by 68.7% in the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the last quarter. LSV Asset Management lifted its stake in shares of Zynex by 45.1% in the 1st quarter. LSV Asset Management now owns 108,935 shares of the company’s stock valued at $1,348,000 after purchasing an additional 33,840 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Zynex by 22.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after purchasing an additional 26,368 shares during the last quarter. Finally, WINTON GROUP Ltd lifted its stake in shares of Zynex by 147.6% in the 2nd quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after purchasing an additional 21,960 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.